415 Capital
VC Fund
Oberhaching, Germany
415 CAPITAL is a specialist venture capital firm that invests in early- and development-stage MedTech companies in Europe, the United States and Israel.They primarily invest in innovative medical device technologies addressing cardiovascular disease: the worldwide leading cause of death and the single largest cost driver in the global healthcaresystem.We are investors AND entrepreneurs: As investors, They have funded 45 MedTech companies in the past 28 years. As entrepreneurs, They have founded, built, and exited several successful European MedTech distribution companies.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 31%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries 415 Capital invests in
Stages 415 Capital invests in
Countries 415 Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series A
- $5.2M–$31M
- Series B
- $35M–$87M
- Series C
- $30M–$80M
Investment Focus
Industry
- Medical Device 8 (50%)
- Health Care 6 (38%)
- Medical 5 (31%)
- Personal Health 2 (13%)
- Robotics 1 (6%)
Stage
- Series A 4 (25%)
- Series B 4 (25%)
- Series C 3 (19%)
- Series E 2 (13%)
- Seed 1 (6%)
Country
- Switzerland 3 (19%)
- United States 3 (19%)
- France 1 (6%)
- Israel 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Azin Parhizgar
Senior Venture Partner
|
Senior Venture Partner | Total investments: 1 | Find email | |
Frank Groenewegen
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Frederik Groenewegen
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
Ruben Osnabrugge
Partner
|
Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Endovascular Engineering
|
Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis. | $80M / Series C / Apr 07, 2026 | |
Supira Medical
|
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $120M / Series E / Mar 26, 2025 | |
|
Endovascular Engineering
|
Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis. | $42M / Series B / Feb 18, 2025 | |
CorFlow Therapeutics
|
CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients. | $48.5M / Series B / Sep 10, 2024 | |
R3 Vascular
|
R3 Vascular is a privately held medical device company developing new therapies for the treatment of peripheral artery disease. | $87M / Series B / May 09, 2024 | |
Hilo
|
Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com. | $30.7M / Series A / Feb 27, 2024 | |
|
Supira Medical
|
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $40M / Series D / Nov 21, 2023 | |
Tricares
|
TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation. | $46.9M / Series C / Sep 15, 2022 | |
|
Supira Medical
|
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $30M / Series C / Feb 28, 2022 | |
Distalmotion
|
Distalmotion is a medical device company founded and based in Lausanne, Switzerland. Our mission is to remove the complexity out of robotic surgery in order to establish a new standard of care, where all patients in general surgery, gynecology and urology have access to best-in-class minimally invasive care. To do so, we have developed a surgicalrobot called Dexter. Designed, developed and manufactured in Switzerland, Dexter integrates the benefits of laparoscopy and robotics. Dexter combines the affordability of laparoscopy with the benefits of robotics through his novel, on-demand approach to robotic surgery. For further information, visit: dexter.surgery and follow us on LinkedIn and Twitter: @Distalmotion. | $90M / Series E / Jan 26, 2022 | |
| See all 16 investments → | |||
Co-Investors
Cormorant Asset Management
4 deals together
The Capital Partnership
4 deals together
M&L Healthcare Investments
3 deals together
Panakes Partners
3 deals together
Unorthodox Ventures
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does 415 Capital invest in?
415 Capital invests primarily in Medical Device, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is 415 Capital's check size?
415 Capital typically joins rounds of $5.2M–$31M at Series A, $35M–$87M at Series B and $30M–$80M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds 415 Capital participates in.
How do I contact 415 Capital?
Public channels for 415 Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at 415 Capital?
The team at 415 Capital includes Azin Parhizgar (Senior Venture Partner), Frank Groenewegen (Managing Director) and Frederik Groenewegen (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
